Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Abstract In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers. And many other anti-PD-L1 antibodies are under clinical trials. Recently, the crystal structures of PD-L1 in co...
Guardado en:
Autores principales: | Hyun Tae Lee, Ju Yeon Lee, Heejin Lim, Sang Hyung Lee, Yu Jeong Moon, Hyo Jeong Pyo, Seong Eon Ryu, Woori Shin, Yong-Seok Heo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b9c8ef6cf5af47aca2205e92c9d3f1e9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea M, et al.
Publicado: (2021) -
Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
por: Nitin Roper, et al.
Publicado: (2021) -
Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
por: Maohua Li, et al.
Publicado: (2021) -
New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu N, et al.
Publicado: (2017) -
Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
por: Grégoire de Streel, et al.
Publicado: (2020)